Cargando…

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

PURPOSE: The safety and efficacy of the combined use of sorafenib and yttrium-90 resin microspheres (Y90 RMS) to treat advanced hepatocellular carcinoma (HCC) is not well established. We determined the incidence of adverse events with this combination therapy in patients with advanced HCC at our ins...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahvash, Armeen, Murthy, Ravi, Odisio, Bruno C, Raghav, Kanwal Pratap, Girard, Lauren, Cheung, Sheree, Nguyen, Van, Ensor, Joe, Gadani, Sameer, Elsayes, Khaled M, Abdel-Wahab, Reham, Hassan, Manal, Shalaby, Ahmed S, Yao, James C, Wallace, Michael J, Kaseb, Ahmed O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994795/ https://www.ncbi.nlm.nih.gov/pubmed/27574586 http://dx.doi.org/10.2147/JHC.S62261

Ejemplares similares

Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib
por: Teyateeti, Ajalaya, et al.
Publicado: (2021)

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients
por: Teyateeti, Ajalaya, et al.
Publicado: (2020)

Temporary Balloon Occlusion of the Common Hepatic Artery for Yttrium-90 Glass Microspheres Administration in a Patient with Hepatocellular Cancer and Renal Insufficiency
por: Smith, Justin, et al.
Publicado: (2013)

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by (90)Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma
por: Kaseb, Ahmed Omar, et al.
Publicado: (2021)

Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma
por: Niekamp, Andrew, et al.
Publicado: (2018)

Minimally invasive image-guided therapies for hepatocellular carcinoma
por: Abdelsalam, Mohamed E, et al.
Publicado: (2016)

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy
por: Hosseini Shabanan, Sedighe, et al.
Publicado: (2022)

Trans-arterial hepatic radioembolisation of yttrium-90 microspheres
por: Murthy, R, et al.
Publicado: (2006)

A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma
por: Zhen, Yanhua, et al.
Publicado: (2019)

Hepatic Abscess following Yttrium-90 Radioembolization in Patients with Surgical Bilioenteric Anastomosis or Compromised Sphincter of Oddi: A Tertiary Cancer Center Experience
por: Agahi, Kevin N., et al.
Publicado: (2022)

Blood flow diversion using the microvascular plug to avoid non target delivery of radioactive microspheres
por: Abdelsalam, Mohamed E., et al.
Publicado: (2020)

Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2015)

Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors
por: Kucuk, Ozlem N, et al.
Publicado: (2011)

Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors
por: Kucuk, N Ozlem, et al.
Publicado: (2011)

A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of (90)Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study
por: Mahvash, Armeen, et al.
Publicado: (2022)

Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres
por: Depalo, Tommaso, et al.
Publicado: (2021)

International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres
por: Levillain, Hugo, et al.
Publicado: (2021)

Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma
por: Gabrielson, Andrew, et al.
Publicado: (2015)

Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors
por: Paprottka, Karolin J., et al.
Publicado: (2021)

Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation
por: Moawad, Ahmed W., et al.
Publicado: (2023)

Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial
por: Vilgrain, Valérie, et al.
Publicado: (2014)

Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases
por: Cosimelli, M, et al.
Publicado: (2010)

Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma
por: Pestana, Roberto Carmagnani, et al.
Publicado: (2018)

Yttrium-90 microsphere induced gastrointestinal tract ulceration
por: South, Christopher D, et al.
Publicado: (2008)

Internal dosimetry for radioembolization therapy with Yttrium‐90 microspheres
por: Fallahpoor, Maryam, et al.
Publicado: (2017)

The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
por: Awiwi, Muhammad O, et al.
Publicado: (2022)

Temporary Reversal of Hepatoenteric Collaterals during (90)Y Radioembolization Planning and Administration
por: Habibollahi, Peiman, et al.
Publicado: (2022)

Comparing voxel-based absorbed dosimetry methods in tumors, liver, lung, and at the liver-lung interface for (90)Y microsphere selective internal radiation therapy
por: Mikell, Justin K, et al.
Publicado: (2015)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial
por: Chan, Stephen Lam, et al.
Publicado: (2022)

Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
por: Nabrinsky, Edward, et al.
Publicado: (2020)

Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
por: Salem, Riad, et al.
Publicado: (2021)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2022)

Yttrium-90 Microsphere Radioembolization for Treatment of Lung Cancer Hepatic Metastases
por: Gaba, Ron C., et al.
Publicado: (2012)

Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate Cancer
por: Bunck, Alexander C., et al.
Publicado: (2017)

Standardizing SPECT/CT dosimetry following radioembolization with yttrium-90 microspheres
por: Kim, S. Peter, et al.
Publicado: (2021)

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
por: Elganainy, Dalia, et al.
Publicado: (2018)

Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial
por: Chauhan, Nikhil, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2vocif6cdsecfkkbaskt7165m8